Start the conversation
We love a good comeback story.
Especially when it involves a developmental-stage biotech firm...
Earlier this year, Trevena Inc. (Nasdaq: TRVN), a clinical-stage biopharmaceutical company received a double dose of bad news for its acute heart failure drug, TRV027, after it failed to meet either of its target outcomes (known as primary and secondary "endpoints" in drug-study jargon).
That news sent its stock down 18% for the day.
This is premium content for Private Briefing subscribers only.